Kidney Disease Clinical Trials in Philadelphia

Showing 61-80 of 210 trials

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

NCT03117309

Phase II trial of nivolumab in 120 treatment naïve patients with ccRCC.

Michael B. Atkins, MD164 participantsStarted Apr 2017

New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +9 more locations

RECRUITINGPHASE2< 1 mile

Ferric Citrate and Chronic Kidney Disease in Children

NCT04741646

We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.

Chronic Kidney Diseases

University of California, Los Angeles160 participantsStarted Jun 2022

Los Angeles, California, United States • Orange, California, United States • San Francisco, California, United States +17 more locations

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Ferric Citrate and Chronic Kidney Disease in Children

Kidney Disease Trials in Other Cities

Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Using Virtual Reality (VR) Models for Preoperative Planning

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Bone in CKD Alkali Response (BICARb Pilot Trial)

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Communication During Hospitalization About Resuscitation Trial

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

Other Conditions in Philadelphia